MedTrace Logo

A Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults

NCT05121506 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2022-06-01

No results posted yet for this study

Summary

The bioavailability of cannabinoids differs greatly for different routes of administration. When applied topically to the skin, they are absorbed through the skin or hair follicles while interacting with receptors to provide localized effects. To gain more information on the potential of this route of administration in therapeutic applications, this open-label study will investigate the skin absorption and bioavailability of CBD and THC delivered trans-dermally.

Conditions

  • Biological Availability
  • Skin Absorption
  • CBD
  • THC

Interventions

COMBINATION_PRODUCT

CBD and THC with GT4 technology

A single topical dose of CBD and THC will be administered with GT4 technology. The material will be provided in a single use pre-filled syringe.

Sponsors & Collaborators

  • KGK Science Inc.

    collaborator INDUSTRY

  • Gefion Canada Inc.

    lead OTHER

Principal Investigators

  • David Crowley, MD · KGK Science Inc.

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-27
Primary Completion
2022-01-18
Completion
2022-01-18

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05121506 on ClinicalTrials.gov